Elucidating the mechanism of action of Mirexus Biotechnologies Inc.'s immunomodulatory phytoglyogen (IM-PhG) in increasing virus vector production

阐明 Mirexus Biotechnologies Inc. 的免疫调节植物糖原 (IM-PhG) 在增加病毒载体产量方面的作用机制

• 批准号: 523780-2018
• 负责人: Mossman, Karen
• 金额: $ 1.75万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=660332
• 关键词: Elucidating; mechanism; action; Mirexus; Biotechnologies

Millions of dollars are spent on the research, development and commercialization of new therapies to treat**virus infections, vaccines, virus-based gene therapy vectors and, more recently, oncolytic viruses that target and**kill cancer. While significant gains have been made in the development of these therapeutic tools, several key**roadblocks remain, including the need to develop more generic antiviral therapies that target a wide range of**known and new emerging viruses and the need to optimize virus-based vaccine and vector production to make**these products commercially viable from both a cost and manufacturing perspective.**Mirexus Biotechnologies is a biomedical company actively developing novel nano-medicines for a variety of**clinical indications. Their technology platform is based on renewable, non-toxic glycogen, or sugar, from corn.**Phytoglycogen (PhG) can be easily altered by chemists. Indeed, one modification was shown to change the**immune stimulating properties of PhG (IM-PhG). More specifically, IM-PhG can decrease the primary immune**response in cells. As a result, a higher yield of viruses can be obtained from the cells, overcoming one of the**current roadblocks to making virus-based therapies.**The goal of this proposal is to understand the mechanism of how IM-PhG alters the environment within the**cell, allowing for a higher level of virus production. To ensure safety and to optimize virus production, it is**critical to understand how IM-PhG is functioning. These studies will also allow "smart engineering" by**chemists of more potent versions of PhG.

数百万美元用于研究、开发和商业化治疗病毒感染的新疗法、疫苗、基于病毒的基因治疗载体，以及最近用于靶向和杀死癌症的溶瘤病毒。虽然在开发这些治疗工具方面取得了重大进展，但仍存在几个关键的障碍，包括需要开发针对广泛的已知和新出现的病毒的更通用的抗病毒疗法，以及需要优化基于病毒的疫苗和载体生产，以使这些产品从成本和制造角度都具有商业可行性。Mirexus Biotechnologies是一家生物医学公司，积极开发用于各种临床适应症的新型纳米药物。他们的技术平台是基于可再生的，无毒的糖原，或糖，从玉米。植物糖原（PhG）可以很容易地被化学家改变。事实上，一种修饰显示出改变PhG的 ** 免疫刺激特性（IM-PhG）。更具体地，IM-PhG可以降低细胞中的初级免疫 ** 应答。因此，可以从细胞中获得更高产量的病毒，克服目前制造基于病毒的疗法的障碍之一。该提案的目标是了解IM-PhG如何改变 ** 细胞内环境的机制，从而允许更高水平的病毒生产。为了确保安全性并优化病毒生产，了解IM-PhG的工作原理至关重要。这些研究也将使 ** 化学家能够“聪明地”设计出更有效的PhG版本。